A73 - Eribulin in metastatic breast cancer: our experience

Abstract

Introduction: Metastatic breast cancer represents an incurable disease but novel agents are able to prolong survival in some cases. Materials and methods: Between January 2012 and February 2015, 31 patients with MBC were observed. All patients had a diffuse disease (bony and visceral metastases), a median age of 55 years (range 40-76) and a performance status (PS ) 0-2 (ECOG). All patients received eribulin over first line (15 patients by 3 line, 16 patients over 3 line), with a dose of 1,23 mg/mq i.v. day 1-8 every 21 days. Median number of cycles was 3,45 (range 1-10). Twenty-six/thirty-one patients had estrogen positive disease, 20/31 patients had progesterone positive disease. 9 patients had HER2 positive status. Twenty-five/thirty-one patients had bony metastases, 14/31 patients had liver metastases, 14/31 patients had lung metastases, 6/31 patients had brain metastases, only one patient had skin lesions. The other lines in patients HR positive and HER 2 positive included one or more hormonal therapies and Her-2 blocked treatments, respectively. Results: At a median follow-up of 12 months, results included: median overall survival of 7,44 months; progression free survival of 2,67 months; partial response in 4 patients; stable disease in 4 patients; progression disease in 23 patients. Overall survival was better in patients only with bony metastases. The main observed all grade toxicities were: leukopenia 58%, febrile neutropenia 48,3%, fatigue 70,9%, anemia 48,3%, algie 41,9%, peripheral neuropathy 9,6%, asma 32,2%, headache 35,4%, stipsis 22,5%, nausea 38,7%, mucositis 48,3%. Conclusions: Our experience on real life confirmed that treatment with eribulin is safe in patients with progressive metastatic breast cancer, with results on efficacy consistent with the previous phase III studies.